Nanomix seeks EUA for COVID-19 rapid antigen panel

2021 02 10 00 21 5783 Coronavirus Receptor Viralentry 400

Nanomix has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its eLab COVID-19 rapid antigen test, which runs on the company's eLab analyzer.

The assay can provide results in 15 minutes from a self-administered nasal swab sample, according to Nanomix. It's suitable for use in a range of settings such as hospitals, nursing homes, assisted living facilities, urgent care centers, and emergency medical care, the firm said.

Page 1 of 34
Next Page